Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

2.

Mezigdomide Combinations Show Promise in Multiple Myeloma

3.

Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?

4.

Prostate cancer explained: From antigen tests to treatment options

5.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot